HNN3.0
Register
Register
Register

Project cooperationUpdated on 22 January 2026

Synthetic & CADD Labs – Design, Synthesis and Extraction of Bioactive Compounds

Researcher - RTDA at University of Cagliari (UNICA)

Cagliari, Italy

About

Synthetic & CADD Labs is a multidisciplinary research group within the Department of Life and Environmental Sciences (DiSVA), specializing in integrated medicinal chemistry approaches that link in silico design (CADD), Synthesis and Extraction of Bioactive Compounds. The group actively contributes to European and international collaborative projects, supporting the progression of early-stage discoveries toward validated therapeutic candidates.

Research Lines

  1. Identification of new molecules with antiviral activity (targeting HIV-RT, EBOV VP35 and VP24, viral helicases from Coronaviruses and Flaviviruses, Flavivirus proteases), antitumor activity (particularly targeting kinases, hCA IX and XII, angiogenesis), antifungal and anti-inflammatory activity (COX-2, IL-6, MCP-1, FAAH), activity on CB2 receptors, opioid receptors, multi-target action, and for the treatment of neurodegenerative diseases.

  2. Synthesis and semi-synthesis of organic molecules with potential pharmacological activity.

  3. Application of Computer-Aided Drug Design (CADD) and virtual screening approaches for the identification of new compounds, Structure-Activity Relationship (SAR) studies, and prediction of drug-like (ADMET) properties.

  4. Application of advanced chemoinformatics protocols and AI-driven data mining for pharmaceutical research and drug design.

  5. Identification and structural elucidation of bioactive compounds from higher plants.

  6. Study of the mechanism of action of biologically active organic compounds.

Equipment

  • 2 HPLC systems: semi-preparative and analytical, with chiral separation capability

  • Flash chromatography system

  • Circular dichroism spectrometer

  • UV-Vis spectrophotometer

  • Microplate reader

  • Polarimeter

  • Microwave reactor for chemical reactions

  • Nitrogen generator

  • Knife mill

  • 4 chemical fume hoods and 1 laminar flow hood

  • 7 workstations (3 GPU-equipped), server, and storage

The group also has access to CESAR’s fee-based services (such as NMR, MS, X-ray, and SPR).

Collaborations

The group is part of the Paul Ehrlich Euro PhD Network.
Most important international collaborations include:

  • Faculty of Life Sciences – Division of Pharmaceutical Chemistry, University of Vienna, Austria

  • Department of Chemistry and Biochemistry, University of Porto, Portugal

  • Semmelweis University, Budapest, Hungary

  • Institute of Pharmaceutical Chemistry, University of Marburg, Germany

  • Faculty of Pharmacy, University of Ljubljana, Slovenia

  • Department of Pharmacology, School of Medicine, Taipei, Taiwan

  • Institute of Biotechnology, Kaunas University of Medicine, Lithuania

  • Institute of Oncology Research, Università della Svizzera italiana, Switzerland

  • Freie Universität Berlin, Institute of Pharmacy, Germany

  • Department of Pharmaceutical Chemistry – Health Research Institute, University of Nantes, France

  • Institute of Organic Chemistry, Department of Chemistry, University of Hamburg, Germany

Collaborations in Italy comprise:

  • Pharmaceutical and Nutraceutical Sciences Section, Department of NEUROFARBA, University of Florence

  • Department of Health Sciences, “Magna Græcia” University, Catanzaro (UMG)

  • IGM CNR, Pavia

  • Institute of Biostructures and Bioimaging (IBB), Naples

The group is particularly interested in participating in Horizon Europe consortia, contributing expertise in:

·       Medicinal chemistry and preclinical drug discovery
·       Antiviral strategies and pandemic preparedness
·       Biomarker-driven translational research
·       Interdisciplinary projects combining chemistry, biology, AI, and digital technologies

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

  • Partner seeks Consortium/Coordinator

Similar opportunities

  • Project cooperation

    Medicinal Chemistry & Drug Discovery for Infectious and Neurodegenerative Diseases

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

    Ioanna Kalograiaki

    Internationalization Research Manager at Centro de Investigaciones Biológicas Margarita Salas-CSIC

    Madrid, Spain

  • Project cooperation

    Expertise offer: synthetic chemistry and process development

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Arlene Bonner

    Research Programme Manager at KelAda Pharmachem

    DUBLIN, Ireland

  • Project cooperation

    Offering expertise in tailored antiviral strategies and viral models generation

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Ilaria Carli

    Principal Research Scientist at IRBM S.p.A.

    Rome, Italy